AlgometRx, Inc. is a medical device start-up that objectively measures pain and drug effect. The company was spun out from Children's National in 2015 by Julia Finkel, M.D., a pediatric anesthesiologist. The device determines pain type and intensity, as well as the suitability of an intervention. The intervention is then fine-tuned as needed to optimize an individual’s pain management. It is currently the only web-enabled mobile device which objectively measures pain and monitors safe use of an opioid or analgesic in patients 30 weeks post conceptual through geriatrics.
AlgometRx is one of eight companies selected out of 250+ by the FDA for Breakthrough Device Status/Early Access pathway for its Rapid Drug Test targeting Opioid Use Disorder. The company is currently in the Research Prototype phase with ongoing clinical trials being conducted at Children's National. Commercial approval of the Rapid Drug Test should occur in 2020.